Education Use Only
For educational use only — Not for clinical decision-making without independent verification
Medical Associates  ·  Department of Nephrology ← Maintenance Hemodialysis module  ·  urinenephrology.org
Clinical Mastery Series  ·  Maintenance Hemodialysis

Dialysate potassium: bath selection and the rule of 7 vs 8

Potassium kinetics, what the outcome data say about each bath, and what the sum rules actually do
Andrew Bland, MD, FACP, FAAP UICOMP · UDPA · Butler COM Reviewed September 2026 22 min read

Bottom line

Part of the Maintenance Hemodialysis mastery module. Potassium in serum and dialysate is reported in mEq/L, which is numerically identical to mmol/L. “2K” means a dialysate (bath) potassium of 2 mEq/L; “pre-HD K” means the serum potassium drawn immediately before the session.

  • 2K and 3K are the evidence-supported working range. In 55,183 DOPPS patients (observational), 3K versus 2K carried the same adjusted mortality (HR 0.96, 95% CI 0.91–1.01) and arrhythmia risk (HR 0.98, 0.88–1.08), with no interaction across four pre-dialysis potassium strata 1.
  • Baths below 2 mEq/L carry a recurring association with in-unit cardiac arrest. Patients who arrested in the dialysis unit were nearly twice as likely to have been dialyzed against 0K or 1K that day (17.1% vs 8.8%) 2. The signal recurs in other cohorts 3,4,5, though not in every analysis 1,6,7.
  • The rule of 7 does not limit the serum-to-dialysate gradient; it enlarges it. Each 1 mEq/L rise in serum potassium lowers the bath by 1 and raises the gradient by 2 mEq/L. What the rule actually targets is an end-of-treatment potassium near 3.5 mEq/L (rule of 7) or 4.0 mEq/L (rule of 8) 8. No peer-reviewed source exists for a “rule of 8,” and neither sum has been tested against outcomes 9.
  • Atrial fibrillation favors the higher bath. 3K versus 2K was associated with 13% fewer new AF diagnoses in older incident patients 10. In the ADAPT crossover trial, 3K plus a potassium binder on non-dialysis days roughly halved device-detected AF episodes compared with 2K alone 11.
  • Changing the bath barely moves the next pre-dialysis potassium—about 0.09 mEq/L per 1 mEq/L change in bath 1. Chronic hyperkalemia is a diet, bowel, drug, binder, and time problem first (see Hyperkalemia on HD).
  • The post-dialysis number is not the patient’s potassium. About 35% of the intradialytic fall returns within an hour and about 70% within six hours 12,13. Never supplement potassium on an immediate post-dialysis value.

1. Potassium kinetics during hemodialysis

Where potassium lives

Total body potassium is about 50 mEq/kg—roughly 3,500 mEq in a 70-kg adult—and only about 2% of it (about 70 mEq) sits in the extracellular fluid 12. The other 98% is inside cells, at a concentration near 150 mEq/L against an extracellular concentration near 4 mEq/L 12. Dialysis can reach only the 2%.

A patient on hemodialysis who eats about 60 mEq of potassium a day remains in positive balance by roughly 45 mEq/day even with optimal gut excretion; cellular uptake keeps most of that load out of the serum between treatments 12. Colonic potassium secretion is two- to threefold higher in dialysis patients than in people with normal kidney function, and fecal potassium output tracks stool volume 12.

Removal during the session

Potassium leaves the blood almost entirely by diffusion across the dialyzer membrane, in proportion to the serum-to-dialysate gradient—the pre-HD serum potassium minus the dialysate potassium 12. Plasma empties faster than cells refill it, so the curve has a characteristic shape: a steep fall in the first hour, a slower fall over the next two, then a plateau. In 14 hyperkalemic patients dialyzed against 1K for 4 hours, serum potassium fell more than 1 mEq/L in the first 60 minutes, another 1 mEq/L over the next 2 hours, and then stopped changing 12,13. The plateau after about 3 hours is reproducible and appears independent of bath potassium across 0–2 mEq/L 12,14.

StudyDesign0K1K2K
Hou 1989 1511 stable patients, each studied on all three baths78.5 mEq removed62.9 mEq50.6 mEq
Zehnder 2001 1412 patients, randomized crossover, glucose-free dialysate117.1 mEq80.2 mEq63.3 mEq

A 0K bath removed 24% more potassium than 1K and 50% more than 2K in the Hou study 15. Urea removal did not change with the potassium bath in the Zehnder crossover 14, so a higher bath does not cost small-solute clearance.

Only about 42% of the potassium removed comes from the extracellular space 13, and removal varies widely between and within patients 12,16. Potassium does not behave like urea; a single-pool equation cannot predict the post-dialysis value 17.

Rebound after the session

Because plasma is emptied faster than cells can refill it, potassium rises again after the needles come out. In the best-characterized study, plasma potassium fell from 5.65 to 3.62 mEq/L during a standardized 4-hour high-flux treatment, then climbed back to 5.01 mEq/L six hours later—despite 107 mEq of potassium removed 13. On average, about 35% of the intradialytic fall is erased within the first hour and nearly 70% by the sixth hour 12. The post-rebound value correlated with the pre-dialysis value, not with how much potassium was removed 13.

Clinical Pearl — the post-dialysis number is not the patient’s potassium

A potassium drawn at the end of treatment captures the bottom of a curve that is already turning upward. Supplementing potassium on that value treats an artifact of timing. The logic cuts the other way in severe hyperkalemia: a reassuring end-of-treatment value can rebound into the danger zone within hours 13.

What else moves potassium during treatment

Anything that drives potassium into cells lowers the serum level faster while removing less potassium from the body.

ModifierEffectEvidence
Higher dialysate bicarbonateFaster serum fall through intracellular shift; total removal unchangedRandomized crossover, 8 patients: serum K at 240 minutes 3.34 (bicarbonate 39), 3.80 (35), and 4.24 mEq/L (27) 18
Glucose-free dialysateLower insulin, more cellular efflux, more removalRemoval tended to be 28% higher without dialysate glucose 16
Insulin–glucose or albuterol before dialysisShifts potassium into cells; reduces what dialysis can remove and may exaggerate rebound12
Higher dialysate sodiumExaggerated post-dialysis rebound (143 vs 138 mEq/L)12

The bicarbonate row matters at the chair: a faster fall without more removal means a larger rebound once the alkalosis resolves.

The gradient and the long interval

The gradient is largest in the first minute of treatment and shrinks as serum potassium falls toward the bath. It drives the speed of the early intradialytic fall, the part of the potassium sawtooth that has long worried nephrologists 19. A rule that lowers the bath as serum potassium rises therefore cannot be a gradient-limiting rule (section 4).

Thrice-weekly schedules leave one gap of up to 72 hours 20, and hyperkalemia (5.5 mEq/L or higher) was 2.0 to 2.4 times as prevalent after the long interval as after a short one in national US cohorts 21.

2. Sudden death, arrhythmia, and serum potassium

Sudden death is the dominant cardiac death

Sudden cardiac death accounts for about 25% of all deaths in patients on dialysis and about two-thirds of cardiac deaths 22. Witnessed arrest in the unit is uncommon per treatment and devastating per patient: 7 per 100,000 sessions in one large series, with 60% dead within 48 hours and 37% hospitalized in the preceding 30 days 2, and 4.5 per 100,000 treatments across 43,200 patients in another 3.

Timing follows the dialysis cycle

StudyFinding
Foley 2011, 32,065 patients 23Day after the long interval versus other days: all-cause death 22.1 vs 18.0, cardiac-arrest death 1.3 vs 1.0, and dysrhythmia admissions 20.9 vs 11.0 per 100 person-years
MiD, 66 implanted loop recorders 241,678 clinically significant arrhythmias in 44 patients—1,461 bradycardias, 14 asystole, 1 sustained VT; highest during the first session of the week and the last 12 hours of the long interval
Wong 2015, 50 implanted monitors 208 sudden deaths, all during the long interval; terminal rhythm severe bradycardia with asystole in each recorded case

The implanted-monitor studies changed the mental model. The terminal rhythm in hemodialysis patients is more often bradycardia and asystole than ventricular tachycardia 20,24—exactly the rhythm hyperkalemia produces.

Serum potassium and outcomes: a U-shaped relationship

  • In 81,013 patients, a pre-dialysis potassium of 4.6–5.3 mEq/L carried the best survival; values below 4.0 or at or above 5.6 were associated with higher mortality 6.
  • In national US cohorts, a potassium of 5.7 mEq/L or higher was associated with death (adjusted HR 1.13, 1.01–1.28), rising to 1.37 (1.16–1.62) at 6.0 or higher 21.
  • A potassium of 5.5 to under 6.0 mEq/L measured on a Friday was associated with higher 96-hour hospitalization risk (adjusted OR 1.68, 1.22–2.30); values of 6.0 or higher were associated with death and emergency visits on any day 25.
  • Hypokalemia is not benign. One quarter of patients with sudden death had a prior monthly potassium below 4 mEq/L 26. Post-dialysis potassium below 3.0 was associated with death (HR 1.44) until pre-dialysis potassium entered the model (HR 1.10, 0.84–1.44); low values both before and after dialysis carried the highest risk (HR 1.72) 27. Lower serum potassium, even within the normal range, was independently associated with incident AF 10.

Atrial fibrillation is common and mostly silent

Loop recorders detected AF in 41% of MiD participants 24. New AF lasting at least 6 minutes appeared within six months in 31% of those without a prior diagnosis, and 83% of patients with detected AF had a CHA2DS2-VASc score of 2 or more 28. When a bath is being chosen, the patient in the chair may well have AF that no one has diagnosed.

3. Evidence bath by bath

How to read this evidence

Almost every comparison of dialysate potassium is observational, and three problems recur. Confounding by indication: low baths go to patients with high potassium, and high potassium is itself dangerous; patients on 1K may also be less adherent and in worse health 5. Prescribed is not delivered: DOPPS had no data on the delivered bath or on post-dialysis potassium 1. Monthly labs, monthly baths: exposure is usually assigned from a monthly value, while the bath is often changed in reaction to one number.

0K

The largest gradient and the most removal (78.5 vs 50.6 mEq per session against 2K) 15. In 11 patients without arrhythmia history or digoxin, a potassium-free bath did not produce new ectopy in 10; the one patient with high-grade ventricular ectopy had it on every bath, worst on 0K 15. No outcome study isolates 0K; arrest analyses grouped it with 1K or with baths of 1.5 or less 2,4. The UK Renal Association states that 0K is no longer used in UK units 29, while one review argues it is appropriate for 3 hours when potassium is 7 mEq/L or higher 8. Certainty: very low; reserve for monitored treatment of severe hyperkalemia.

1K

This is where the literature disagrees most.

  • Harm (observational): in-unit arrest cases were nearly twice as likely to have been on 0K or 1K that day (17.1% vs 8.8%) 2. Among 502 arrest cases and 1,632 matched controls, a bath below 2 mEq/L was associated with arrest, unexplained by pre-dialysis potassium 3. In the MADRAD cohort (624 patients), 1K versus 2K carried an adjusted mortality HR of 1.70 (1.01–2.88), concentrated in patients with pre-dialysis potassium of 5 or higher (HR 2.87, 1.51–5.46); only 47 patients were on 1K 5.
  • Benefit or neutrality (observational): in 81,013 patients, higher dialysate potassium in hyperkalemic patients was associated with higher mortality 6. In a Taiwanese single-center cohort, 1K used selectively for potassium above 5.5 was associated with less sudden cardiac death (HR 0.33, 0.13–0.85) 7. In DOPPS, 1.0–1.5 versus 2.0–2.5 carried a mortality HR of 1.04 (0.97–1.11) 1.
Conflicting evidence — does 1K hurt or help the hyperkalemic patient?

All of these studies are observational and confounded by indication, they measure different endpoints, and very few patients in any cohort had potassium above 6 mEq/L 5,6,7. The net benefit of 1K in hyperkalemic patients is unknown, so 1K belongs among monitored, time-limited tools, not standing prescriptions.

2K and 3K

2K has been the reference and the dominant prescription: 2.0–2.5 mEq/L was prescribed to 75% of US patients in DOPPS phase 5 1. Compared with 3K, it was associated with more sudden death in DOPPS 4 and more incident AF in older incident US patients 10, yet those signals did not translate into a mortality difference in the largest cohort 1.

3K versus 2K in DOPPS (55,183 patients, 20 countries): mortality HR 0.96 (0.91–1.01), arrhythmia composite HR 0.98 (0.88–1.08), HRs 0.94–1.03 across four pre-dialysis potassium strata, and an instrumental-variable estimate of 0.99 (0.92–1.07) per 1 mEq/L higher bath 1. In 15,190 Medicare patients aged 67 or older starting dialysis, 3K versus 2K was associated with less incident AF (fully adjusted HR 0.87, 0.78–0.96); the abstract reports this as 14% and the results text as 13% 10. The cost is less removal: in hyperkalemic patients, higher baths were associated with higher mortality 6. Certainty is moderate that 2K and 3K carry similar mortality, and low for the AF benefit.

4K

4K is used rarely (3% of an Alberta cohort), and its higher mortality in the base model (HR 1.74 versus 2K) disappeared after adjustment for inflammation and malnutrition 30; it showed no AF benefit 10. Its rationale is strongest with digoxin: 8 of 9 patients with dialysis-related ventricular arrhythmias on 2K were taking it, and a 3.5 mEq/L bath reduced ectopy in 4 of 6 re-studied patients 31. Certainty: very low; reasonable for persistent pre-dialysis hypokalemia with weekly potassium checks 9.

The gradient studies

In 830,741 patient-intervals from 62,388 Medicare patients (observational), gradients of 4 to under 5 and 5 or more mEq/L were associated with 30% and 51% higher adjusted odds of same-day hospitalization than a gradient of 2 to under 3 (OR 1.30 and 1.51) 32. The absolute scale is small (3.29 versus 3.99 per 1,000 intervals); there was no association with death, and cardiac arrest was not measured 32. The DOPPS authors add a methodological warning: gradient variation is driven mostly by serum potassium, so a gradient analysis largely re-measures serum potassium 1.

Randomized and crossover evidence

ADAPT (randomized crossover) enrolled 88 adults with pre-dialysis potassium of 5.1–6.5 mEq/L, all with implanted cardiac monitors. Eight weeks of 2K without a binder were compared with eight weeks of 3K plus sodium zirconium cyclosilicate (SZC) on non-dialysis days, titrated to a pre-dialysis potassium of 4.0–5.5; both arms used dialysate calcium 2.5 mEq/L 11.

Outcome3K + SZC2K, no binderEffect
Adjudicated AF episodes of 2 minutes or longer (primary)9.7 per person-year13.4 per person-yearRate ratio 0.52 (0.41–0.65); RRR 48%; NNT not derivable (all 296 episodes occurred in 9 of 88 patients)
Clinically significant arrhythmias (bradycardia, VT, asystole)6.8 per person-year10.2 per person-yearRate ratio 0.47 (0.38–0.58); RRR 53%
Patients with hypokalemia3358Per-period denominators not reported in the abstract
Critical appraisal — what ADAPT can and cannot tell you

Two interventions changed at once, so ADAPT cannot show that 3K alone beats 2K, or that a sum of 8 beats a sum of 7. The control arm had no interdialytic potassium management, the endpoint is a device-detected rhythm surrogate, and all AF episodes came from 9 participants. A published corrigendum could not be retrieved; treat specific ADAPT numbers as abstract-verified 11,33.

Stepped baths and profiling. In 60 hyperkalemic patients on twice-weekly dialysis, 2K for 1 hour then 0K for 3 hours lowered post-dialysis potassium to 3.48 versus 3.72 mEq/L with constant 2K; the trial was far too small to establish safety 34. In a randomized crossover of 42 patients with dialysis-related ectopy, a constant-gradient bath that decreased to 2.5 mEq/L reduced premature ventricular complexes per hour by 36% 35. These are small studies with surrogate endpoints 36,37.

4. The rule of 7 versus the rule of 8

Where the rules come from

The rule of 7 chooses a dialysate potassium so that pre-dialysis serum potassium plus dialysate potassium equals about 7 mEq/L. The rule of 8 makes the sum 8. The rule of 7 is better documented as folklore than as science. A 2018 review called it an informal algorithm advocated for decades and noted its potential for large serum-to-dialysate gradients 9. A second 2018 review recommended it for a 3-hour treatment in severe hyperkalemia, reasoning that the average of serum and bath potassium predicts the end-of-treatment value 8. No primary source establishing the rule of 7 was found in PubMed searches, and no peer-reviewed source for a “rule of 8” was found at all; it appears to be a local or teaching variant shifted up by 1 mEq/L.

The arithmetic

Write Ks for pre-dialysis serum potassium and Kd for the bath. Under the rule of 7, Kd = 7 − Ks, so the gradient Ks − Kd = 2Ks − 7. Under the rule of 8, the gradient = 2Ks − 8. For every 1 mEq/L rise in serum potassium, both rules lower the bath by 1 and raise the gradient by 2 mEq/L. The rule of 8 runs exactly 1 mEq/L behind the rule of 7 at every serum value. Neither caps the gradient.

Pre-HD KRule of 7 bathGradientRule of 8 bathGradient
4.03K14K0
4.52.5 (2K/3K)23.5 (3K/4K)1
5.02K33K2
5.51.5 (1K/2K)42.5 (2K/3K)3
6.01K52K4
6.50.5 (0K/1K)61.5 (1K/2K)5
7.00K71K6

Half-integer results must be rounded to a bath the unit stocks, and the rounding direction is a clinical decision the rule does not make.

The rule does not “avoid rapid removal”

A common teaching says the sum rule limits the gradient. The algebra shows the opposite: at a serum potassium of 6.0, the rule of 7 produces a gradient of 5 and the rule of 8 a gradient of 4, both in the top categories associated with short-term hospitalization 32. The rule’s own proponent states its purpose plainly: the amount of potassium removed increases as the potassium concentration increases 8.

What the rule actually targets

If the end-of-treatment potassium lands near the midpoint of the starting serum value and the bath, then end-of-treatment K ≈ (Ks + Kd) ÷ 2. Under the rule of 7 that is (Ks + 7 − Ks) ÷ 2 = 3.5 mEq/L whatever the starting value; under the rule of 8 it is 4.0 mEq/L. Its real logic is a constant end-of-treatment target, not a constant gradient. Most studies with paired pre- and post-dialysis values land within 0.5 mEq/L of that average 8:

StudyPre-HD KBathPredicted endObserved end
Blumberg 1997, 4 h 12,135.651K3.333.62
Chandra 2025, 4 h, constant 2K 345.982K3.993.72
Chandra 2025, 2K for 1 h then 0K 346.00Time-weighted 0.53.253.48

Three limits apply. The approximation assumes a conventional 3- to 4-hour treatment, where the plateau makes it roughly work 12. Anything that moves potassium into cells shifts it 12,18. And it predicts the nadir, not the post-rebound value: in the Blumberg patients, the 3.6 end-of-treatment value was 5.0 six hours later 13.

What the rules can and cannot do

They can give a consistent, teachable starting point that scales removal to the potassium load; in the middle of the potassium range they map onto 2K–3K, the band with the best evidence 1; and they encode a target end-of-treatment potassium 8. They cannot limit the gradient; account for treatment time, clearance, recirculation, ongoing potassium release, shifting therapies, or the cardiac substrate; predict the post-rebound or next pre-dialysis value 1; or claim outcome validation. No study has compared the rule of 7 with the rule of 8, and no trial has tested either against any alternative 9.

5. Practical bath selection

Before changing any bath

  1. Confirm the number. Hemolysis and other measurement errors are frequent, particularly for samples drawn far from the laboratory 29.
  2. Know the day. A value after the long interval is the week’s peak 21; a Friday value of 5.5–6.0 carries more short-term risk than the same value midweek 25.
  3. Look at the trend. One value is an event; two of three is a pattern.
  4. Find the cause. Missed or shortened treatment, dietary load, constipation, a new medication, hyperglycemia, bleeding, or tissue breakdown.
  5. Check the patient. Symptoms, rhythm, and cardiac history matter more than a 0.3 mEq/L difference.

Bath by pre-dialysis potassium

The table below synthesizes the UK Renal Association principle of “the highest dialysate potassium that is sufficient to control pre-dialysis hyperkalaemia,” with baths of 1 to 3 mEq/L for most patients 29; a published algorithm that keeps 2K from 4.1 to 6.4 and adds binder, diet, and longer treatment before 1K, with at least weekly potassium checks whenever the bath is below 2 or above 3 9; and the outcome data above. These are expert-judgment defaults, not trial-proven thresholds.

Pre-HD K (mEq/L)Stable patient, isolated valueRecurrent (2 of last 3)AF, structural heart disease, digoxin, or QT-prolonging drugsRecheck / escalate
Below 3.53K; look for the cause4K by nephrologist order; weekly K until stable 93K–4K; check magnesium; digoxin level if applicable 38Notify nephrologist; recheck next session
3.5–4.03K3K (4K only if values stay below 3.5) 93K–4KRecheck within 1–2 weeks if on 2K
4.1–5.0Keep the current 2K or 3KSame3K preferred 10Routine monthly
5.1–5.5Keep 3K if isolated; 2K if already on it2K, or 3K plus an interdialytic binder 113K plus binder preferred over dropping to 2K 10,11Sooner if Friday or symptomatic 25
5.6–6.02K for this treatment2K plus binder, diet, bowel, and time review2K; add binder; avoid 1KRepeat pre-HD K at the next treatment
6.1–6.42K; confirm not hemolyzed; notify2K plus binder plus extra time or session; 1K only by explicit order with weekly K 92K; notify; ECGRepeat before next treatment
6.5 or higher, or ECG change or symptomsUrgent: bath by nephrologist order, commonly 1K–2K; 0K only with continuous monitoring 12 (see Hyperkalemia on HD)Call now

Two deliberate departures from the sum rules are built in. Between 5.6 and 6.4 the table holds 2K where the rule of 7 would drop to 1K, because harm associations with sub-2 baths are the most recurrent finding in the observational literature 2,3,4,5 and the published algorithm makes the same choice 9. At the low end it holds 3K where the rule of 8 would reach for 4K, because 4K has almost no supporting data 10,30.

Pre-HD potassium resulted. Is the sample valid (hemolysis, timing, lab error)? If doubtful, repeat before acting.
K 6.5 or higher, ECG change, or symptoms? Call the nephrologist now: monitor, treat, dialyze.
↓ if no
Below 4.0
3K; 4K only if persistently below 3.5. Find the cause; check magnesium and digoxin.
4.1 to 5.5
Keep the working bath, 2K to 3K. With AF, favor 3K plus a binder.
5.6 to 6.4
2K this treatment; repeat pre-HD K next session. Recurrent: full workup; 1K only by order with weekly K.
Figure 1. Bath selection after a pre-dialysis potassium result. Expert-judgment defaults synthesized from 9,10,12,29; not trial-tested thresholds.

An isolated dietary spike versus a recurrent problem

A stable patient who ate a holiday meal and arrives at 6.0 mEq/L has a different problem from a patient who arrives at 6.0 every Monday. For the first, 2K for the session and a repeat pre-dialysis value at the next treatment is enough. For the second, the bath is the last lever to pull, not the first: a 1 mEq/L lower bath lowered the next pre-dialysis potassium by less than 0.1 mEq/L, and the DOPPS authors concluded that diet education and binders deserve more attention than bath changes 1. A dietary explanation does not make a high value safe 21,25.

Cardiac substrate: AF, digoxin, QT-prolonging drugs

  • Atrial fibrillation. 3K versus 2K was associated with fewer new AF diagnoses, and lower serum potassium within the normal range with more AF 10. ADAPT supports 3K plus interdialytic potassium control, not a higher bath alone 11.
  • Digoxin. Among 120,864 incident patients, digoxin use was associated with 28% higher mortality (HR 1.28), with risk per ng/mL concentrated where pre-dialysis potassium was below 4.3 (HR 2.53) 38. A digoxin-treated patient should not be on a sub-2 bath; 3K is the reasonable default.
  • QT-prolonging drugs. In DOPPS, amiodarone was associated with sudden death 4; in a case-control study, QT-prolonging drugs were not associated with in-unit arrest 39. Lower serum potassium and lower ionized calcium were each associated with longer QTc 40. Avoid combining QT-prolonging drugs with sub-2 baths and with low dialysate calcium (see Dialysate calcium, bicarbonate, magnesium, and glucose).

Hypokalemia-prone patients

Poor intake, vomiting or diarrhea, recent hospitalization, well-controlled insulin-treated diabetes, and high dialysate bicarbonate all push pre-dialysis potassium down, and the post-dialysis value may sit well below 3.0 27. A 3K bath is the starting point; 4K is reasonable when pre-dialysis values stay below 3.5, with weekly checks 9. The same algorithm advises avoiding dialysate magnesium below 1 mEq/L and dialysate bicarbonate above 35 mEq/L in these patients 9.

Every reactive change needs a recheck

One potassium a month and one bath decision a month is how mismatches happen: a bath lowered for one high value stays in place after the cause resolves 9. The Karnik investigators recommended re-evaluating the dialysate prescription on an ongoing basis, especially after hospitalization; 37% of their arrest patients had been hospitalized within 30 days 2.

Clinical Pearl — give every reactive bath change an expiration date

When a bath is changed because of one value, order the recheck at the same time: a pre-dialysis potassium at the next treatment for any value of 6.0 or higher, and within a week for any bath below 2 or above 3 9. Write the plan to revert when the value returns to baseline. A bath change without a recheck is how a temporary fix becomes a standing 1K prescription.

Evidence gaps

  • No randomized trial of bath potassium on hard outcomes. ADAPT changed bath and binder together and measured device-detected rhythm 11.
  • The rule of 7 and the rule of 8 have never been compared or tested against any outcome 9.
  • 0K and 4K are nearly absent from outcome datasets 10,30.
  • Hyperkalemic patients on 1K: the literature points in both directions, with very few patients above 6 mEq/L in any cohort 5,6,7.
  • Post-dialysis potassium is rarely measured, and its independent prognostic value is doubtful once pre-dialysis potassium is known 27.
  • Delivered versus prescribed bath is not captured in registries 1; point-of-care potassium before each treatment is untested 9.

At the chair

For dialysis nurses and technicians

Know which day of the week a pre-dialysis potassium was drawn: a value after the long interval is the week’s peak. A bath below 2 mEq/L is a deliberate, time-limited order with a recheck attached, not a routine prescription. Report a pre-dialysis potassium of 6.5 or higher, symptoms, or ECG change before starting. Do not give potassium on an end-of-treatment value.

Nursing card N1: Potassium bath selection — do this, call when, don’t, and why

The physician’s written order and the unit protocol always govern.

Also in this module

References

References are carried from a reference-checked evidence review (September 2026) and renumbered for this page. Each was checked against its PubMed record, full text, or the issuing agency’s document.

  1. Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2017;69(2):266-277. PMID: 27866964
  2. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350-357. PMID: 11422771
  3. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 2011;79(2):218-227. PMID: 20811332
  4. Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2012;7(5):765-774. PMID: 22403271
  5. Ferrey A, You AS, Kovesdy CP, et al. Dialysate potassium and mortality in a prospective hemodialysis cohort. Am J Nephrol. 2018;47(6):415-423. PMID: 29879714
  6. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(5):999-1007. PMID: 17702709
  7. Huang CW, Lee MJ, Lee PT, et al. Low potassium dialysate as a protective factor of sudden cardiac death in hemodialysis patients with hyperkalemia. PLoS One. 2015;10(10):e0139886. PMID: 26440515
  8. Abuelo JG. Treatment of severe hyperkalemia: confronting 4 fallacies. Kidney Int Rep. 2018;3(1):47-55. PMID: 29340313
  9. Pun PH. Dialysate potassium concentration: should mass balance trump electrophysiology? Semin Dial. 2018;31(6):569-575. PMID: 30027592
  10. Hu A, Liu S, Montez-Rath ME, et al. Associations of serum and dialysate potassium concentrations with incident atrial fibrillation in a cohort study of older US persons initiating hemodialysis for kidney failure. Kidney Int Rep. 2023;8(2):305-316. PMID: 36815107
  11. Charytan DM, Winkelmayer WC, Granger CB, et al; ADAPT Investigators. Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney Int. 2025;107(1):169-179. PMID: 39490411
  12. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial. 2001;14(5):348-356. PMID: 11679104
  13. Blumberg A, Roser HW, Zehnder C, Müller-Brand J. Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrol Dial Transplant. 1997;12(8):1629-1634. PMID: 9269640
  14. Zehnder C, Gutzwiller JP, Huber A, Schindler C, Schneditz D. Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal. Nephrol Dial Transplant. 2001;16(1):78-84. PMID: 11208997
  15. Hou S, McElroy PA, Nootens J, Beach M. Safety and efficacy of low-potassium dialysate. Am J Kidney Dis. 1989;13(2):137-143. PMID: 2916568
  16. Sherman RA, Hwang ER, Bernholc AS, Eisinger RP. Variability in potassium removal by hemodialysis. Am J Nephrol. 1986;6(4):284-288. PMID: 3777037
  17. Feig PU, Shook A, Sterns RH. Effect of potassium removal during hemodialysis on the plasma potassium concentration. Nephron. 1981;27(1):25-30. PMID: 7219633
  18. Heguilén RM, Sciurano C, Bellusci AD, et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant. 2005;20(3):591-597. PMID: 15687112
  19. Weisberg LS, Rachoin JS. The safety of low-potassium dialysis. Semin Dial. 2010;23(6):556-560. PMID: 21166879
  20. Wong MC, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm. 2015;12(10):2047-2055. PMID: 26111801
  21. Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study. Am J Nephrol. 2016;44(3):179-186. PMID: 27592170
  22. Hung AM, Hakim RM. Dialysate and serum potassium in hemodialysis. Am J Kidney Dis. 2015;66(1):125-132. PMID: 25828570
  23. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011;365(12):1099-1107. PMID: 21992122
  24. Roy-Chaudhury P, Tumlin JA, Koplan BA, et al. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93(4):941-951. PMID: 29395340
  25. Brunelli SM, Du Mond C, Oestreicher N, Rakov V, Spiegel DM. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis. 2017;70(1):21-29. PMID: 28111027
  26. Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006;69(12):2268-2273. PMID: 16672908
  27. Ohnishi T, Kimachi M, Fukuma S, Akizawa T, Fukuhara S. Postdialysis hypokalemia and all-cause mortality in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2019;14(6):873-881. PMID: 31048327
  28. Koplan BA, Winkelmayer WC, Costea AI, et al. Implantable loop recorder monitoring and the incidence of previously unrecognized atrial fibrillation in patients on hemodialysis. Kidney Int Rep. 2022;7(2):189-199. PMID: 35155858
  29. Ashby D, Borman N, Burton J, et al. Renal Association clinical practice guideline on haemodialysis. BMC Nephrol. 2019;20(1):379. PMID: 31623578
  30. Al-Ghamdi G, Hemmelgarn B, Klarenbach S, et al. Dialysate potassium and risk of death in chronic hemodialysis patients. J Nephrol. 2010;23(1):33-40. PMID: 20091484
  31. Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int. 1980;17(6):811-819. PMID: 6447822
  32. Brunelli SM, Spiegel DM, Du Mond C, et al. Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients. Nephrol Dial Transplant. 2018;33(7):1207-1214. PMID: 28992343
  33. Charytan DM, Winkelmayer WC, Granger CB, et al; ADAPT Investigators. Corrigendum to "Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate…". Kidney Int. 2025;107(6):1123. PMID: 40404254
  34. Chandra A, Rao N, Kulshreshtha MR. Controlled potassium reduction using dialysate profiling in hyperkalemic hemodialysis patients: a randomized study. Int J Artif Organs. 2025;48(11):813-818. PMID: 41185428
  35. Redaelli B, Locatelli F, Limido D, et al. Effect of a new model of hemodialysis potassium removal on the control of ventricular arrhythmias. Kidney Int. 1996;50(2):609-617. PMID: 8840293
  36. Santoro A, Mancini E, London G, et al. Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal. Nephrol Dial Transplant. 2008;23(4):1415-1421. PMID: 18065796
  37. Muñoz RI, Montenegro J, Salcedo A, et al. Effect of acetate-free biofiltration with a potassium-profiled dialysate on the control of cardiac arrhythmias in patients at risk: a pilot study. Hemodial Int. 2008;12(1):108-113. PMID: 18271851
  38. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550-1559. PMID: 20576808
  39. Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(5):797-803. PMID: 23371957
  40. Kim ED, Watt J, Tereshchenko LG, et al. Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the PACE study. BMC Nephrol. 2019;20(1):133. PMID: 30999887